A bill approved by a Florida House subcommittee regarding substitution of biosimilar drugs for their brand-name counterparts protects drugmaker profits at the expense of patients and payers, says PCMA President and CEO Mark Merritt. Drugmakers "want expensive brand name drugs to be used because they'll profit from that," Merritt said. "When a generic is just as good as a brand, a patient should have access to the more affordable drugs."

Related Summaries